Overall rank by patents
#2,026
Across all tracked assignees
USPTO PatentsView assignee record - 197 granted patents across 34 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).
The verdict
Sorin holds 197 US patents across 34 technology areas, rank #2,026 of 50,000 tracked assignees.
Sorin CRM SAS has been granted 197 US utility patents between 2015 and 2025, placing Sorin CRM SAS at rank #2,026 across all assignees tracked by PlainPatent. This portfolio spans 34 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.2 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Sorin CRM SAS is one of the more focused assignees in the PatentsView dataset. By volume, Sorin sits between Intersil Americas Llc (197 patents, rank #2,022) and Nektar Therapeutics (196 patents, rank #2,030) - the closest US assignees by grant volume. The composite Innovation Score of 53.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 61 grants, compared with 136 in the 2015–2019 window, a -55% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Sorin CRM SAS's 17.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 34 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sorin CRM SAS against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Intersil Americas LLC
197 patents
Oculus VR, LLC
197 patents
Pismo Labs Technology Limited
197 patents
PsiQuantum Corp.
197 patents
Securus Technologies, LLC
197 patents
TIMOTION TECHNOLOGY CO., LTD.
197 patents
SORIN CRM SAS
197 patents
Biomet Sports Medicine, LLC
196 patents
Nektar Therapeutics
196 patents
What this shows Sorin holds 197 patents at rank #2,026, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #2,026 in granted patent volume.
Other assignees with the most granted patents in Sorin's primary technology class.
Sorin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 28 | 14.2% |
| 2016 | 31 | 15.7% |
| 2017 | 31 | 15.7% |
| 2018 | 27 | 13.7% |
| 2019 | 19 | 9.6% |
| 2020 | 9 | 4.6% |
| 2021 | 18 | 9.1% |
| 2022 | 13 | 6.6% |
| 2023 | 11 | 5.6% |
| 2024 | 8 | 4.1% |
| 2025 | 2 | 1.0% |
Top 15 of 34 technology areas
Overall rank by patents
#2,026
Across all tracked assignees
53.9 out of 100
How to use this portfolio
Sorin's 197 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.